SEC Filing Analysis: Natera, Inc. (NTRA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director Jonathan Sheena filed a Form 144 notice proposing the sale of 21,064 shares valued at approximately $8.16 million pursuant to a pre-scheduled Rule 10b5-1 plan.
• Market Impact: Negligible market impact expected given the pre-arranged nature and small relative size (~0.015% of market cap).

Company Information

Field	Value
Company	Natera, Inc.
Ticker Symbol	NTRA
CIK	0001604821
Industry	Medical Laboratories

Insider Information

Field	Value
Name	Sheena Jonathan
CIK	0001646649
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	Form 144
Transaction Date	2026-09-23
Transaction Code	S (Proposed)
Security Type	Common Stock
Shares Involved	21,064
Price Per Share	~$387.55
Total Value	$8,163,402.00
Shares Owned After	N/A (Form 144)
Ownership Type	Direct / Indirect (Caraluna Trusts/LLCs)

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$8,163,402.00
% of Market Cap	0.015%
Shares Transacted	21,064
% of Shares Outstanding	0.015%
Post-Transaction Ownership	N/A
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a $53.25 billion market valuation, an $8.16M proposed sale accounts for just 0.015% of total market capitalization, making it routine portfolio rebalancing.
• Dilution & Ownership Impact: The shares sold are original founders shares issued in April 2012, generating no secondary share dilution.
• Trading Mechanism: This planned transaction is executed under a Rule 10b5-1 trading plan adopted on June 11, 2026, removing discretionary timing concerns.

Market Impact Analysis

• Stock Impact Direction: Neutral
• Reasoning: The trade represents a de minimis proportion of circulating shares and follows a pre-arranged 10b5-1 schedule.
• Expected Volume Impact: Minimal to none; orderly execution through Charles Schwab & Co., Inc.
• Sentiment Indicator: Neutral

Additional Context

• Trading Plan: Adopted on June 11, 2026, conforming to standard cooling-off guidelines under Rule 10b5-1.
• Past Sales: The reporting insider has conducted structured incremental sales over the preceding 3 months as part of orderly liquidity diversification.